U.S., Nov. 25 -- ClinicalTrials.gov registry received information related to the study (NCT07245927) titled 'Post-registration Trial of the Non-immunogenic Staphylokinase in Massive Pulmonary Embolism' on Nov. 17.
Brief Summary: The aim of FORPE Registry is to study the safety and efficacy of the non-immunogenic staphylokinase in patients with massive pulmonary embolism in routine clinical practice.
Study Start Date: June 01
Study Type: OBSERVATIONAL
Condition:
Pulmonary Embolism Acute Massive
Intervention:
DRUG: Non-immunogenic staphylokinasenon-immunogenic staphylokinase 15 mg as a single intravenous bolus Other Names: Fortelyzin(R)
Non-immunogenic staphylokinase 15 mg as a single intravenous bolus
Recruitment Status: RECRUITING...